Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Pignochino

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pathologica|January 31, 2006
[Stem cells: overview]W Piacibello, Y Pignochino
Scientific Reports|March 10, 2018
Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone MicroenvironmentM Fioramonti, V Fausti, F Pantano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2011
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group studyG Grignani, E Palmerini, P Dileo, et al.
Oncoimmunology|May 4, 2018
CD44v6 as innovative sarcoma target for CAR-redirected CIK cellsV Leuci, G M Casucci, G Grignani, et al.
BMC Genomics|June 7, 2018
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinomaC Peraldo-Neia, P Ostano, G Cavalloni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pathologica|January 31, 2006
[Stem cells: overview]W Piacibello, Y Pignochino
Scientific Reports|March 10, 2018
Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone MicroenvironmentM Fioramonti, V Fausti, F Pantano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2011
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group studyG Grignani, E Palmerini, P Dileo, et al.
Oncoimmunology|May 4, 2018
CD44v6 as innovative sarcoma target for CAR-redirected CIK cellsV Leuci, G M Casucci, G Grignani, et al.
BMC Genomics|June 7, 2018
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinomaC Peraldo-Neia, P Ostano, G Cavalloni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Pageof 1